<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Large Vessel Occlusion Stroke &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/large-vessel-occlusion-stroke/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 14 Dec 2025 06:39:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Large Vessel Occlusion Stroke &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>GLP-1 Agonist Trial in Large Vessel Occlusion</title>
		<link>https://bioengineer.org/glp-1-agonist-trial-in-large-vessel-occlusion/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 14 Dec 2025 06:39:22 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[and key findings: **GLP-1 agonists]]></category>
		<category><![CDATA[Based on the article content]]></category>
		<category><![CDATA[focusing on the core themes]]></category>
		<category><![CDATA[here are 5 appropriate tags]]></category>
		<category><![CDATA[Large Vessel Occlusion Stroke]]></category>
		<category><![CDATA[Neuroprotection]]></category>
		<category><![CDATA[novelty]]></category>
		<category><![CDATA[Reperfusion Therapy Adjunct]]></category>
		<guid isPermaLink="false">https://bioengineer.org/glp-1-agonist-trial-in-large-vessel-occlusion/</guid>

					<description><![CDATA[In a groundbreaking advancement at the intersection of endocrinology and neurology, a recent phase 2 randomized trial has unveiled promising therapeutic potential for glucagon-like peptide-1 receptor (GLP-1R) agonists in the treatment of large vessel occlusion (LVO) stroke patients undergoing reperfusion therapy. This pioneering study, published in 2025 in Nature Communications, spearheaded by Wang, Ko, Leung, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">307606</post-id>	</item>
	</channel>
</rss>
